Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.

Nigim F, Kiyokawa J, Gurtner A, Kawamura Y, Hua L, Kasper EM, Brastianos PK, Cahill DP, Rabkin SD, Martuza RL, Carbonell WS, Wakimoto H.

Target Oncol. 2019 Jul 12. doi: 10.1007/s11523-019-00654-4. [Epub ahead of print]

PMID:
31301014
2.

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.

Lee TJ, Nair M, Banasavadi-Siddegowda Y, Liu J, Nallanagulagari T, Jaime-Ramirez AC, Guo JY, Quadri H, Zhang J, Bockhorst KH, Aghi MK, Carbonell WS, Kaur B, Yoo JY.

Mol Cancer Ther. 2019 Jun;18(6):1127-1136. doi: 10.1158/1535-7163.MCT-18-0953. Epub 2019 Mar 29.

PMID:
30926634
3.

Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966.

Lapteva M, Del Río-Sancho S, Wu E, Carbonell WS, Böhler C, Kalia YN.

Sci Rep. 2019 Jan 31;9(1):1030. doi: 10.1038/s41598-018-36966-0.

4.

β1 integrin: Critical path to antiangiogenic therapy resistance and beyond.

Jahangiri A, Aghi MK, Carbonell WS.

Cancer Res. 2014 Jan 1;74(1):3-7. doi: 10.1158/0008-5472.CAN-13-1742. Epub 2013 Dec 10. Review.

5.

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.

Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK.

Cancer Res. 2013 May 15;73(10):3145-54. doi: 10.1158/0008-5472.CAN-13-0011. Epub 2013 May 3.

6.

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK.

Clin Cancer Res. 2013 Apr 1;19(7):1773-83. doi: 10.1158/1078-0432.CCR-12-1281. Epub 2013 Jan 10.

7.

Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.

DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aghi MK.

Clin Cancer Res. 2012 May 15;18(10):2930-42. doi: 10.1158/1078-0432.CCR-11-2390. Epub 2012 Apr 3.

8.

Molecular MRI enables early and sensitive detection of brain metastases.

Serres S, Soto MS, Hamilton A, McAteer MA, Carbonell WS, Robson MD, Ansorge O, Khrapitchev A, Bristow C, Balathasan L, Weissensteiner T, Anthony DC, Choudhury RP, Muschel RJ, Sibson NR.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6674-9. doi: 10.1073/pnas.1117412109. Epub 2012 Mar 26.

9.

Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.

Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK.

Cancer Res. 2012 Apr 1;72(7):1773-83. doi: 10.1158/0008-5472.CAN-11-3831. Epub 2012 Mar 23.

10.

The vascular basement membrane as "soil" in brain metastasis.

Carbonell WS, Ansorge O, Sibson N, Muschel R.

PLoS One. 2009 Jun 10;4(6):e5857. doi: 10.1371/journal.pone.0005857.

11.

Migration of perilesional microglia after focal brain injury and modulation by CC chemokine receptor 5: an in situ time-lapse confocal imaging study.

Carbonell WS, Murase S, Horwitz AF, Mandell JW.

J Neurosci. 2005 Jul 27;25(30):7040-7. Erratum in: J Neurosci. 2005 Aug 10;25(32):table of contents.

12.
13.
14.
15.
16.

Adaptation of the fluid percussion injury model to the mouse.

Carbonell WS, Maris DO, McCall T, Grady MS.

J Neurotrauma. 1998 Mar;15(3):217-29.

PMID:
9528921

Supplemental Content

Loading ...
Support Center